Atlas Trials

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma

Clinical trial NCT00304525 · COMPLETED

Trial details

NCT number
NCT00304525
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Melanoma
Start date
2006-04-01
Primary completion
2013-11-01
Enrollment
104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.